Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dose-ranging Double-blind, Placebo-controlled Phase 2 Trial of GV101 for Weight Loss in Healthy Obese Participants

NCT06979505 is registered in ClinicalTrials.gov with Graviton Bioscience Corporation as lead sponsor.

NCT NCT06979505
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06979505 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dose-ranging Double-blind, Placebo-controlled Phase 2 Trial of GV101 for Weight Loss in Healthy Obese Participants
Lead sponsor
Graviton Bioscience Corporation
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2025
Completion date
January 28, 2026
Enrollment
131 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

weight management